Clinical Program for VTE Prevention in Cancer

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Vermont

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if a new clinical program can help doctors better adhere to guidelines for preventing blood clots in cancer patients receiving treatment at home. It will test whether the program assists doctors in conducting risk assessments and prescribing appropriate blood-thinning medications (anticoagulants) to those in need. Patients will receive care from doctors trained in this new program as part of their regular cancer treatment. This trial suits cancer patients about to begin new treatments with participating doctors. As an unphased trial, it offers patients the chance to contribute to enhancing cancer care practices.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with your doctor.

What prior data suggests that this clinical program is safe for patients?

Studies have shown that preventing blood clots in cancer patients is both effective and safe. A successful approach involves a program that helps doctors and patients follow recommended practices to reduce clot risk.

Past research indicates these methods are well-tolerated, with patients usually handling them without major issues. One study found that preventing blood clots in patients with active cancer was both effective and safe.

Although blood-thinning medications can sometimes cause bleeding, this trial focuses on a program to manage that risk. The goal is to ensure the right steps are followed to keep patients safe. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the clinical program for VTE prevention in cancer because it offers a new approach to tackling blood clots in cancer patients. Unlike standard treatments that typically involve anticoagulants like heparin or warfarin, this program is likely exploring innovative strategies or protocols to enhance patient safety and efficacy. The goal is to discover more effective ways to prevent venous thromboembolism (VTE) in a population at high risk, potentially leading to better outcomes and fewer side effects.

Who Is on the Research Team?

Karlyn Martin, MD

Principal Investigator

University of Vermont

Are You a Good Fit for This Trial?

This trial is for ambulatory cancer patients who are starting systemic treatment. It's designed to see if a modified clinical program can better prevent blood clots compared to usual care. Clinicians involved will learn about and implement VTE prevention guidelines.

Inclusion Criteria

Clinicians must be practicing oncologists at the study clinic site (UVMMC)

I am diagnosed with cancer and will start a new treatment under a study doctor's care.

Exclusion Criteria

Not applicable.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Education and Risk Assessment

Participant clinicians receive education about VTE prevention recommendations and carry out risk assessment, anticoagulation discussions, and document the results

4 weeks

Implementation

Implementation of the modified clinical program to improve adherence to guideline recommendations for VTE prevention

30 days

Follow-up

Participants are monitored for safety and effectiveness after the implementation of the clinical program

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Clinical program

Trial Overview

The study tests whether a new clinical program increases the number of patients assessed for clotting risk and receiving proper blood-thinning medication, as opposed to standard practices without this structured program.

How Is the Trial Designed?

Group I: Clinical program Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

University of Vermont

Lead Sponsor

Trials

283

Recruited

3,747,000+

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10562910/

Venous thromboembolism prevention in cancer care

Evidenced-based interventions have been developed to prevent venous thromboembolism (VTE) in ambulatory patients with cancer.

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S2667193X24001935

Venous thromboembolism prevention program ...

Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic. JCO ...

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT07292376

Implementing VTE Prevention in Ambulatory Cancer Care

The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous ...

4.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e18677

Results from ACT4CAT study. | Journal of Clinical Oncology

Conclusions: Prevention of VTE in ambulatory patients with active cancer found effective and safe. Apart from the Khorana score, specific ...

5.

annalsofoncology.org

annalsofoncology.org/article/S0923-7534(22)04786-X/fulltext

Venous thromboembolism in cancer patients

Anticoagulant treatment of VTE in cancer patients is effective but may be associated with increased bleeding. LMWH or DOACs are effective treatments and ...